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Abstract— The aim of this study was to investigate the 
relationships between depression and occurrence of 
chemotherapy induced prospective memory impairment in 
patients with breast cancer (BC).The 63 BC patients 
before and after chemotherapy were administered with the 
self-rating depression scale (SDS) and a battery of 
cognitive neuropsychological tests including event-based 
and time-based prospective memory (EBPM and TBPM, 
respectively) tasks. The changes in their prospective 
memory and cognitive neuropsychological characteristics 
before and after chemotherapy were compared. Compared 
with the scores before chemotherapy, the EBPM score 
exhibited a statistically significant difference after 
chemotherapy (t = 6.069, P < 0.01), while the TBPM score 
showed no significant difference (t = 1.087, P > 0.05). 
Further, compared with the patients without depression, 
the patients with depression exhibited a statistically 
significant difference in the EBPM score (t = -4.348, P < 
0.01), while the TBPM scores did not show a statistically 
significant difference between the two groups (t = -1.260, 
P > 0.05). Post-chemotherapy, EBPM and overall 
cognitive functions in BC patients merged with depression 
were found to decline, while TBPM did not show a 
significant change, suggesting that the combination of 
chemotherapy and depression might be related with the 
occurrence of post-chemotherapy EBPM impairment. 
Keywords— Breast cancer, depression, cognitive 
impairment, prospective memory. 
 
I. INTRODUCTION 
Chemotherapy-related cognitive impairment (CICI) refers 
to the impairment of cognitive functions-such as memory, 
information processing speed, and attention- that occurs in 
cancer patients during or after chemotherapy. Some 
studies1 have suggested that the impact of CICI in long-
term survivors of breast cancer (BC) was even worse than 
the recurrence and metastasis of BC itself, and that it had 
become an important factor that might affect patients’ 
quality of life. Recently, several studies have examined 
CICI in BC. Psycho-Oncology, Journal of Clinical 
Oncology, and other such journals have published the 
latest research and systematic reviews in this field2,3. It 
was found that CICI in BC survivors exhibited significant 
heterogeneity. Evidently, The CICI in BC have become a 
hot topic in the field of psycho-oncology. 
In recent years, a large number of studies have found that 
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BC patients exhibit cognitive impairment after 
chemotherapy. For instance, Park et al. found that BC 
patients exhibited subjective and objective cognitive 
impairments after chemotherapy4. Similarly, Wefel et al. 
found that one or more cognitive functions tend to decline 
in BC patients after chemotherapy 5. Some studies also 
suggested that the brain exhibited certain heterogeneity 
after BC chemotherapy. Jim et al. showed that the changes 
of language and visuospatial functions in the brain were 
significant after BC chemotherapy2. Chen et al. performed 
multidimensional neuropsychological scale tests on 42 BC 
patients before and after chemotherapy, and found that the 
patients exhibited different levels of impairment in 
memory, attention, social cognition, and other aspects after 
chemotherapy6. Some recent studies have also found that 
the brain memory impairment was prominent after BC 
chemotherapy, and that the extent of impairment was also 
different among different memory components. Cheng et 
al. found that after BC chemotherapy, the brain exhibited 
prospective memory (PM) impairment, which mainly 
manifested as the impairment of event-based prospective 
memory (EBPM)7. Thus, CICI in BC has been found to be 
influenced by a number of factors. Most recently, Paquet 
et al. studied 80 cases of early BC survivors and found that 
fatigue after BC chemotherapy could facilitate PM 
impairment in patients with early BC, and it was thought 
that the symptoms of fatigue had certain correlation with 
memory impairment in patients8. 
PM is the memory required for future plans or intentions 
and the memory component most closely related to human 
daily lives. McDaniel et al. divided PM into event-based 
prospective memory (EBPM) and time-based prospective 
memory (TBPM)9. Recent studies suggested that the BC 
patients with CICI presented PM impairment, which was 
mainly exhibited as EBPM impairment8. However, the 
specific impacting factors are not clear yet. Studies have 
found emotion to be an important factor affecting 
memory10 ,and depression was one of the most common 
mental disorders in BC patients11. Depression could affect 
physiological functions, treatment compliance, cognitive 
functions, and quality of life in BC patients12. However, 
whether CICI and PM impairment were related to patients’ 
depression is not clear yet. Particularly, there is no report 
about whether depression is related to chemotherapy-
induced EBPM. 
This study attempted to investigate whether chemotherapy 
and depression in BC patients were together related to the 
occurrence of PM impairment. The study subjects included 
63 BC patients after chemotherapy. Cognitive 
neuropsychological tests to assess PM were used to 
investigate the impact of chemotherapy along with 
depression on the changes in PM in BC patients. 
 
II. MATERIALS AND METHODS 
Clinical data of patients enrolled 
We selected 63 patients who underwent adjuvant 
chemotherapy after BC surgery in the Department of 
Oncology and Department of Beast Surgery, The Second 
Affiliated Hospital of Anhui Medical University, from 
October 2013 to August 2014. Out of them, 59 cases were 
identified as those of invasive ductal carcinoma and 4 as 
invasive lobular carcinoma by postoperative pathology. 
The tumor differentiation grade ranged from I-III, with 18 
cases in Grade I, 38 in Grade II, and 7 in Grade III. The 
postoperative staging ranged from I-III. All subjects had 
undergone at least 5 years of formal education, were right-
handed, had normal or corrected vision, and acceptable 
binaural hearing. Therefore, they all could cooperate with 
the tests. This study was conducted in accordance with the 
declaration of Helsinki. This study was conducted with 
approval from the Ethics Committee of Anhui Medical 
University. Written informed consent was obtained from 
all participants. 
 
Grouping criteria 
The following were the inclusion criteria for BC patients: 
 
International Journal of Environment, Agriculture and Biotechnology (IJEAB)                             Vol-2, Issue-3, May-Jun- 2017 
http://dx.doi.org/10.22161/ijeab/2.3.23                                                                                                                    ISSN: 2456-1878 
www.ijeab.com                                                                                                                                                                           Page | 1186  
had undergone modified BC radical mastectomy; had a 
clear histopathological diagnosis; initially treated but did 
not undergo endocrine therapy or brain radiotherapy after 
surgery; had a life expectancy of ≥3 months; planned for 
standard FAC chemotherapy after surgery (fluorouracil 
500 mg/m2, intravenous infusion on the first day, 
adriamycin 50 mg/m2, intravenous infusion on the first day, 
cyclophosphamide 500 mg/m2, intravenous bolus on the 
first day, with a 21-day cycle for a total of 6 cycles) and 
conduct normal activities of daily living; had a Karnofsky 
functional score (KPS) ≥80 points or ECOG score on 
physical performance within 0 to 1 point; and did not have 
any hearing, vision, language, or other dysfunction. 
The exclusion criteria were having late cachexia or distant 
metastasis; had undergone endocrine therapy, brain 
radiotherapy, or other adjuvant therapies; had significant 
anxiety, depression, and other mental disorders that could 
disturb their participation in the study; had other physical 
or mental illnesses that could lead to cognitive impairment; 
had a history of alcohol or drug dependency; were 
administered other drugs that could improve cognitive 
functions, such as donepezil; had intracranial metastases 
and other abnormalities according to the brain CT or MRI; 
had an ECOG score of >2 points; and had other severe 
diseases related to the heart, liver, kidney, brain, and 
hematopoietic system. 
 
Depression assessment 
The SDS was developed by Zung (1965), as a self-rating 
scale to measure the severity of depression and its changes 
during treatment. According to Chinese standards, the 
degrees of depression were divided into 53-62 points: mild 
depression, 63-72 points: moderate depression, and >72 
points: severe depression. 
 
Cognitive neuropsychological tests 
The mini-mental status examination (MMSE), verbal 
fluency test (VFT), and digital span (DS) were used to 
assess cognitive functioning. A battery of tests was 
administered to all subjects to assess general cognitive and 
memory functions. MMSE was used to assess the 
cognitive functions, including time and spatial orientation, 
short-term memory, calculation, language, and visuospatial 
skills. The Verbal Fluency Test (VFT),in which the 
subjects were asked to name as many animals as possible 
within one minute, was used to evaluate the executive 
function. The Digit Span (DS) test, in which the subjects 
were asked to recall a series of numbers after hearing them 
in a randomized order, was used to measure working 
memory and attention. The total score was determined by 
the number of digits recalled in a correct serial order. 
 
PM tests 
The EBPM test: Before the test, the subjects were 
instructed to pick out two words belonging to a subclass 
from each card in the subsequent trials. When the two 
selected words represented animals (target word), the 
subjects had to tap the table once. At the end of the test, 
the subjects were instructed to speak out their telephone 
number (without any other hint at the end of the test). The 
test stimuli included 32 cards with 12 high-frequency and 
real-meaning Chinese words, among which 10 words 
belonged to a larger category, while the other 2 words 
belonged to a subclass. In the learning stage, the subjects 
were asked to speak out two words of a subclass as the 
first two cards were for trial. In the trial, the first card did 
not include the target word, while the second card 
contained the target word. Following the instructions that 
were provided before test, when the target word, i.e., a 
kind of animal, appeared, the subjects’ EBPM task was to 
tap the table once. The other EBPM task was to remember 
to speak out their phone number when the card selection 
ended. 
Recording method: We referred to the method developed 
by  McDaniel and Einstein13. Thus, when a predetermined 
target word appeared, the subject was expected to perform 
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a target behavior, and the number of times the same was 
correctly executed was recorded as EBPM score. This test 
comprised a total of six target cards (numbered as 5, 10, 15, 
20, 24, and 29). When the target card appeared, the correct 
response was recorded as 1 point, and remembering to 
speak out the phone number at end of the test was recorded 
as 2 points. Thus, the total score on the EBPM test was 8 
points. 
The TBPM test: Before the test, the subjects were 
instructed to tap the table once at 5, 10, and 15 min, 
respectively after the test began, to choose the maximum 
and minimum numbers from each card. One clock was 
placed in front of the subjects, such that the subjects could 
be sure about the time through this clock. The clock was 
set at 0:00:00 at the beginning of the test. Test stimuli 
included 100 cards, when the clock started, the subjects 
were presented the cards one at a time. Each card had 12 
double digits, out of which the subjects had to select the 
minimum and maximum numbers to complete the TBPM. 
Meanwhile, the subjects were also expected to complete 
another TBPM task (i.e., taping the table at 5, 10, and 15 
min after the commencement of the test). The test was 
stopped at 17 min. 
Recording method: Referring to the method developed by 
McDaniel and Einstein13, the number of times the target 
behavior was correctly executed at correct time intervals 
was recorded as the TBPM score. If the action was 
performed within 10 seconds before or after each target 
time, it would be record as 2 points. Further, if it was 
performed within 30 seconds, it was recorded as 1 point. 
Thus, the total score on the TBPM test was 6 points. 
 
Statistical analysis 
The SPSS 17.0 software was used for data processing. Test 
scores before and after chemotherapy were compared 
using a paired-sample t-test, while the general information 
and neuropsychological characteristics between the 
depression and non-depression groups were compared 
using two independent samples t-tests. 
 
III. RESULTS 
General information 
In total, 63 BC patients were evaluated after chemotherapy, 
out of which, 29 patients were found to have depression, 
while 34 patients were not. There was no significant 
difference in age (50.66 ± 7.76 vs. 47.35 ± 8.56) and years 
of education (7.90 ± 3.36 vs. 9.44 ± 3.57), and other 
general characteristics between the depression and non-
depression groups (P > 0.05). 
Comparison of depression, neuropsychological tests, and 
PM 
Compared with the results before chemotherapy, SDS and 
MMSE scores exhibited a statistically significant 
difference after chemotherapy, while frontal fluency and 
DS showed no statistically significant differences. 
Table 1 
Further, as compared with the results before chemotherapy, 
the EBPM score exhibited a statistically significant 
difference after chemotherapy (t = 6.069, P < 0.01), while 
the TBPM score showed no significant difference (t = 
1.087, P > 0.05) 
Table 2 
Comparison of neuropsychological tests and PM 
After chemotherapy, the MMSE and VFT scores of the 
depression group were found to be significantly lower than 
those of the non-depression group, while the DS score 
showed no statistically significant difference. 
Table 3 
 
Further, as compared with the depression group, the 
EBPM score of the non-depression group was significantly 
different (t = -4.348, P < 0.01), while the TBPM score 
showed no significant difference (t = -1.260, P > 0.05). 
Table 4 
 
IV. DISCUSSION 
Currently, CICI in BC patients is one of the major issues 
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concerning the field of psycho-oncology. The high 
incidence and relatively long survival time of BC has 
provided an important window for studies on CICI in BC 
patients. Existing studies suggested that CICI in BC 
patients was mainly related to the following areas: memory, 
attention, executive function, information processing speed, 
language function, and visuospatial function14-16. The 
present study found that BC patients exhibited an overall 
decline in cognitive functions after chemotherapy, which is 
similar to the findings of other studies15,16. Meanwhile, we 
also found that chemotherapy, when combined with 
depression, might be associated with EBPM impairment. 
Memory is one of the important human cognitive functions, 
which refers to the psychological processes through which 
the brain accumulates and preserves individual experiences. 
Therefore, it has a prominent place in all human mental 
activities. According to the time of occurrence of an event, 
memory could be divided into retrospective memory (RM) 
and PM13. Other than RM, PM is one of the most 
important forms of human memory. EBPM refers to the 
memory required to carry out certain actions when a 
specific event occurs, for example, remembering to go 
shopping after work. Volle et al. found that the 
spontaneous extraction of EBPM information was related 
to the functions of the prefrontal cortex17. In one of our 
previous studies, we found that the patients with frontal 
lobe impairment tended to exhibit significant EBPM 
impairment18. The present study suggested that the BC 
patients with depression had significant EBPM impairment 
after chemotherapy, which might be related with the 
changes in the prefrontal structures and insufficient 
functioning of the same. 
Depression is a common mental state in women with BC. 
Since the 1960s, foreign countries have paid attention to 
BC women’s depression. Fann et al.retrospectively 
analyzed the occurrence of depression within 1 year after 
BC diagnosis over the last 20 years19, and found that its 
incidence after BC surgery was about 10% to 25%. 
Similarly, Luutonen et al. 20studied and reported that the 
incidence of depressive symptoms in patients with newly 
diagnosed BC was up to 32.1%. Further, in 19.4% of them 
the depression was moderate or mild, while in 12.7% 
patients it was moderate or severe. Chemotherapy is one of 
the important treatment to BC patients. However, most BC 
patients have had a certain fear towards chemotherapy. 
Additionally, the incidence of depression in BC patients 
after chemotherapy has been reported to be even higher 
than patients before chemotherapy. Lekovich et al.21 
statistically analyzed the incidence of depression in 95 BC 
patients within 1-6 months after chemotherapy, and 
reported it to be up to 67%. Recently, certain studies have 
found that depression in BC patients was not temporary, 
and some patients have even exhibited high levels of 
depressive symptoms after the completion of treatment22-24. 
Studies have also found that not all BC patients suffer 
from depression, and that those with depression have also 
exhibited differences in the degree, manifestation, and 
duration of depression19-21. The main causes of depression 
in BC patients have been reported as follows: shock from 
the BC diagnosis; special importance of breasts to females, 
and as most BC patients prefer surgical treatment, the 
physical change would result in a double whammy 
physically and mentally; socio-demographic factors such 
as age, educational level, employment status, household 
income, obesity, and marital status (all these have been 
reported to affect patient’s depression; however, this idea 
is still controversial); the side effects of treatment, such as 
the impact of chemotherapy on fertility, sexual function, 
perimenopausal period, and related health problems, which 
have been reported to cause significant anxiety and pain in 
BC patients25. The present study found that depression 
caused by various factors might be involved in the 
occurrence of CICI in BC patients. The mechanisms of 
CICI in BC patients are not clear yet. However, recently 
there has been active research in this field. Several studies 
have found that CICI is manifested differently in BC 
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patients, with many impacting factors and complex 
pathogeneses. Therefore, several multi-disciplinary studies, 
such as those on molecular biology and neuroimaging, 
have been conducted. The present study provided evidence 
for the incidence of EBPM impairment after BC 
chemotherapy from the perspective of the effect of 
emotions on memory, thus providing a clinical basis for 
further exploring the biological mechanisms of EBPM 
impairment after BC chemotherapy. 
Previous studies have confirmed that patients with 
depression exhibited significant cognitive impairment. The 
present study found that the MMSE, VFT, and EBPM 
scores in depressed patients after BC chemotherapy were 
lower than those in the non-depressed patients. Therefore, 
we believe that chemotherapy, together with depression, 
would further aggravate cognitive impairment in BC 
patients. Particularly, the changes in EBPM were 
prominent, suggesting that the combined effect of BC 
chemotherapy and post-chemotherapy depression might be 
one of the important factors affecting EBPM impairment 
after BC chemotherapy. 
In conclusion, this study showed that the BC patients with 
post-chemotherapy depression would exhibit a decline in 
their general cognitive function and EBPM, suggesting 
that depression might be associated with the occurrence of 
PM impairment after BC chemotherapy. 
 
V. CONCLUSION 
This study indicated that EBPM and overall cognitive 
functions in BC patients merged with depression were 
found to decline, while TBPM did not show a significant 
change, suggesting that the combination of chemotherapy 
and depression might be related with the occurrence of 
post-chemotherapy EBPM impairment. 
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Table.1: Comparison of depression and neuropsychological background testing between the 2 groups before and after 
chemotherapy 
Group N    SDS                MMSE VFT DS 
Before chemotherapy 63 37.44±6.74＃ 27.84±1.73＃ 11.32±1.59 7.66±0.60 
After chemotherapy 63 48.31±13.09 26.19±1.77 11.27±1.71 7.67±0.51 
Note: # P<0.05. Abbreviations: SDS, the self-rating depression scale; MMSE, mini-mental state examination; VFT, verbal 
fluency test; DS, Digit span. 
 
Table.2: Comparison of EBPM and TBPM scores between the 2 groups before and after chemotherapy 
Group N    EBPM              TBPM 
Before chemotherapy 63 3.10±1.12＃ 4.95±0.99 
After chemotherapy 63 1.87±1.14 4.75±1.14 
Note：＃ P0.01. Abbreviations: EBPM, event-based prospective memory; TBPM, time-based prospective memory. 
 
Table.3: Comparison of neuropsychological background testing between the depression group and the non-depression group 
after chemotherapy: 
Group N   MMSE VFT DS 
Depression group 29 25.14±1.19# 10.69±1.50# 7.55±0.57 
Non-depression group 34 27.01±1.67 11.76±1.76 7.76±0.43 
Note: # P<0.05. Abbreviations: MMSE, mini-mental state examination; VFT, verbal fluency test; DS, Digit span. 
 
Table.4: Comparison of EBPM and TBPM scores between the 2 groups after chemotherapy 
Group N    EBPM              TBPM 
Depression group 29 1.28±0.96＃ 4.55±1.18 
Non-depression group 34 2.38±1.04 4.91±1.08 
Note：＃ P0.01. Abbreviations: EBPM, event-based prospective memory; TBPM, time-based prospective memory. 
 
 
 
 
